Pathkey.AI Ltd (ASX:PKY) Shares Rise on TrialKey Contract: Here’s Why

Sonal Goyal

11 November 2026 01:17 PM AEDT

Pathkey.AI Ltd (ASX:PKY) Shares Rise on TrialKey Contract: Here’s Why

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Pathkey.AI shares traded up 6.67% at $0.016 during the 11 November 2026 trading session.
Subsidiary TrialKey signed a services agreement with Paradigm Biopharmaceuticals to evaluate a Phase 3 osteoarthritis study.
The agreement has a total value of A$25,000 plus GST.

During the Trading session on 11 November 2026, Pathkey.AI Ltd (ASX:PKY) shares were trading at $0.016 by late morning, up 6.67%. The S&P/ASX 200 (ASX:XJO) was down about 0.06% at 9,123.90 at 12:19 pm over the same period. Pathkey.AI operates through its Subsidiary TrialKey, which provides clinical trial design and assessment services. On 10 November 2026, the company announced that TrialKey had signed a services agreement with Paradigm, on the day before the trading move.

Services Agreement With Paradigm

TrialKey signed a services agreement with Paradigm Biopharmaceuticals, which is under administration, to provide an independent evaluation of its PARA_OA_012 Phase 3 osteoarthritis study. The agreement has a total value of A$25,000 plus GST.

Scope of the Evaluation

The company said TrialKey will evaluate the trial’s design, conduct and analysis to identify potential reasons for Paradigm’s interim findings. It will also assess whether alternative approaches could have affected those results. The findings will inform TrialKey’s recommendations for Paradigm’s consideration.

Broader Service Offering

Pathkey.AI said TrialKey’s 14 live services help identify study risks, compare alternative designs and assess model benefits and costs. Recent internal testing showed improved predictions across nine clinical trial outcomes, according to the company.

Next Priorities

The company said the Paradigm appointment converts its broader offering into contracted project work. Further priorities include delivery, additional biotech engagements and clinical research organisation pilot licensing.

Sector Context

Clinical trial design and analytics services are part of a wider effort across the pharmaceutical and biotechnology sectors to improve trial efficiency and understand trial outcomes. Small listed providers in this area often depend on a small number of engagements, and their shares can move on individual contract news.

Key Risks

The contract is small in value, at A$25,000 plus GST, and the findings may not explain the interim result. Paradigm is under administration, which adds uncertainty about the engagement and its payment. TrialKey’s broader services depend on winning further biotech and CRO engagements, and the company’s pilot licensing plans are still at an early stage.

What to Watch Ahead

Investors will be looking for the delivery of the Paradigm evaluation, further biotech engagements and progress on CRO pilot licensing. The company’s next quarterly or financial report will show how the broader offering is developing.

Final Word

Pathkey.AI’s trading session on 11 November 2026 came after TrialKey signed a contracted evaluation of a Phase 3 study. Further engagements will show whether the company’s broader services gain traction.

FAQs

Q: What is TrialKey?

A: TrialKey is the subsidiary of Pathkey.AI that provides clinical trial design and assessment services.

Q: What is the value of the Paradigm agreement?

A: The agreement has a total value of A$25,000 plus GST.

Q: What study is TrialKey evaluating?

A: TrialKey is evaluating the PARA_OA_012 Phase 3 osteoarthritis study run by Paradigm.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.